Breaking News

Almac Launches GMP High Throughput Peptide Mfg. Service

Completes MHRA registration at its Technopole campus near Edinburgh, Scotland

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Almac Group has successfully completed MHRA registration of its High Throughput GMP Peptide manufacturing facility at its Technopole campus near Edinburgh, Scotland. The facility manufactures neoantigen derived peptides for use in the production of patient specific, individualized cancer vaccines.   Almac Sciences has been involved in the individualized cancer vaccine field for several years and its facility and systems have been set up to enable GMP compliant manufacture and release of 20-30 ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters